Molecular Partners (NASDAQ:MOLN) Trading Up 7.1% – Still a Buy?

Molecular Partners AG (NASDAQ:MOLN)’s stock price was up 7.1% on Monday . The company traded as high as $5.44 and last traded at $5.44. Approximately 2,138 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 22,256 shares. The stock had previously closed at $5.08.

Analysts Set New Price Targets

Separately, Leerink Partnrs upgraded shares of Molecular Partners to a “strong-buy” rating in a research report on Monday, October 7th.

Molecular Partners Stock Performance

The company has a market cap of $214.33 million, a PE ratio of -2.47 and a beta of 1.00. The business’s 50-day moving average is $5.67 and its 200 day moving average is $5.96.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.